دورية أكاديمية
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
| العنوان: | Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. |
|---|---|
| المؤلفون: | Prat, A, Cheang, MCU, Galván, P, Nuciforo, P, Paré, L, Adamo, B, Muñoz, M, Viladot, M, Press, MF, Gagnon, R, Ellis, C, Johnston, S |
| المساهمون: | Cheang, Chon |
| بيانات النشر: | AMER MEDICAL ASSOC |
| سنة النشر: | 2016 |
| المجموعة: | The Institute of Cancer Research (ICR): Publications Repository |
| مصطلحات موضوعية: | Humans, Bone Neoplasms, Breast Neoplasms, Nitriles, Triazoles, Quinazolines, Receptor, erbB-2, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Disease-Free Survival, Treatment Outcome, Proportional Hazards Models, Retrospective Studies, Adult, Aged, 80 and over, Middle Aged, Female, Kaplan-Meier Estimate, Biomarkers, Tumor, Letrozole, Lapatinib |
| الوصف: | IMPORTANCE: The value of the intrinsic subtypes of breast cancer (luminal A, luminal B, human epidermal growth factor receptor 2 [currently known as ERBB2, but referred to as HER2 in this study]-enriched, and basal-like) in the metastatic setting is currently unknown. OBJECTIVE: To evaluate the association of the intrinsic subtypes of breast cancer with outcome and/or benefit in hormone receptor (HR)-positive metastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Unplanned retrospective analysis of 821 tumor samples (85.7% primary and 14.3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor. Tumor samples were classified into each subtype using the research-based PAM50 classifier. Prior neoadjuvant/adjuvant antiestrogen therapy was allowed. Patients with extensive symptomatic visceral disease were excluded. Treatment effects were evaluated using interaction tests. MAIN OUTCOMES AND MEASURES: Primary and secondary end points were progression-free survival and overall survival. RESULTS: The median (range) age was 62 (31-94) years. Intrinsic subtype was the strongest prognostic factor independently associated with progression-free survival and overall survival in all patients, and in patients with HER2-negative (n = 644) or HER2-positive (n = 157) diseases. Median progression-free survival differed across the intrinsic subtypes of clinically HER2-negative disease: luminal A (16.9 [95% CI, 14.1-19.9] months), luminal B (11.0 [95% CI, 9.6-13.6] months), HER2-enriched (4.7 [95% CI, 2.7-10.8] months), and basal-like (4.1 [95% CI, 2.5-13.8] months). Median OS also differed across the intrinsic subtypes: luminal A (45 [95% CI, 41-not applicable {NA}] months), luminal B (37 [95% CI, 31-42] months), HER2-enriched (16 [95% CI, 10-NA] months), and ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | Print; 1294; application/pdf |
| اللغة: | English |
| تدمد: | 2374-2437 2374-2445 |
| العلاقة: | JAMA oncology, 2016, 2 (10), pp. 1287 - 1294; https://repository.icr.ac.uk/handle/internal/346Test |
| DOI: | 10.1001/jamaoncol.2016.0922 |
| الإتاحة: | https://doi.org/10.1001/jamaoncol.2016.0922Test https://repository.icr.ac.uk/handle/internal/346Test |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.CE069BB5 |
| قاعدة البيانات: | BASE |
| تدمد: | 23742437 23742445 |
|---|---|
| DOI: | 10.1001/jamaoncol.2016.0922 |